Gan to kagaku ryoho. Cancer & chemotherapy · 2007
[A case of ascending colon cancer with enlarged metastatic lymph nodes around superior mesenteric arterial root that responded dramatically to S-1 and CPT-11 combination chemotherapy].
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koga Masakazu, Kamitani Takanori, Futami Kitaro, Arima Sumitaka
Аннотация
A 50-year-old man was admitted because of right lateral abdominal pain, easy fatigue and anemia. An endoscopic examination revealed advanced ascending colon cancer, and abdominal CT scan demonstrated enlarged metastatic lymph nodes of superior mesenteric arterial circumference. The Serum CEA rose considerably. The preoperative diagnosis was cStage IV (SS, N(4), P(0), H(0), M(-)), and right colectomy was performed on March 2, 2005. The metastatic lymph nodes around the superior mesenteric arterial root macroscopically remained. From the 20th postoperative day, we started combination chemotherapy using S-1 plus CPT-11 as one course for three weeks. S-1 (120 mg/body/day) was orally administered for 2 weeks continuously, and CPT-11 (80 mg/m(2)) was done intravenously on day 1 and 8. Serum CEA was normalized in the middle of 3 courses. Moreover, after 13 courses, a complete response (CR) was noted on the follow-up abdominal CT scan. No severe side effect more than grade 2 was observed, there was no interruption of the dosage, and PS was sufficiently maintained kept enough through this combination chemotherapy. The course has been without metastasis, recurrence and a rise of serum CEA now in the 16th postoperative month. S-1/CPT-11 combination chemotherapy is a promising and effective cure for unresectable progressive recurrent colorectal cancer in future.